HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Swiss Firm Amazentis' Supplement With Urolithin A For Age-Related Muscle Decline Debuts In US

Executive Summary

Nestle-backed Amazentis says clinical studies show its Timeline Cellular Nutrition delivers “significant” improvement in muscle strength after four months and delivers six times more urolithin A than pomegranate juice. Direct-to-consumer sales currently are available only in the US.

You may also be interested in...



Prevagen ‘Improves Memory’ Claims Will Be Qualified Under Class Action Settlement

Quincy Bioscience doesn’t admit to “any liability or wrongdoing of any kind associated with the claims alleged” in settlement to complaint in federal court in Florida, but agrees to pay plaintiffs refunds of 30% of the MSRP for its supplements, up to $70 per individual claimant.

Health And Wellness Market News: Nestle Invests In Amazentis, CBD Launches, More

PepsiCo promotes Steven Williams to CEO of North American division; Nestle invests in Amazentis to create supplements with its natural bioactive that improves mitochondrial function; Anlit introduces probiotic chews for women; CBD topical pain relief from Omax; more news.

US Meeting Set For CBDs’ Impact On Pregnancies, Gender-Specific Biological, Psychosocial Effects

FDA schedules public meeting for 19 November to discuss sex and gender differences in the use and response to cannabidiols. The meeting will address the issue of CBD use in pregnancy, for which no human data currently is available.

Topics

Related Companies

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel